Literature DB >> 7645922

Prognostic value of cathepsin-D expression in female breast cancer.

M Aaltonen1, P Lipponen, V M Kosma, S Aaltomaa, K Syrjänen.   

Abstract

Expression of an acidic lysosomal protease, cathepsin-D (CD), was analysed immunohistochemically in a series of 151 breast carcinomas with special reference to its prognostic significance, Strong expression of CD was detected in 22% of cases. This intense expression was significantly associated with a number of established prognostic factors, including the non-ductal type of carcinoma (p = 0.0243) and metastases at the time of diagnosis (p = 0.0068). On the other hand, high expression of CD was not related to the lymph-node status, tumour size, ER/PR content or histological grade. Patients with CD overexpression has a significantly lower survival probability (p = 0.0478) than did the patients with low expression of this protease. The relationship between the high expression of CD and short disease-free survival was almost significant (p = 0.0519). Intense immunostaining of CD was associated with a significantly impaired disease outlook in patients with confirmed lymph node metastasis (N+) (p = 0.0137) but not in those with negative lymph nodes (N-) (p = 0.0620). In Cox's multivariate analysis, expression of CD had no independent prognostic value over the conventional prognostic factors. The results suggest that expression of CD is of borderline significance in evaluating the intrinsic malignancy of female breast cancer in general. The potential of CD as a prognostic factor in specific subgroups of breast cancers will be the subject of further studies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7645922

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  Cathepsin D detected by automated and quantitative immunohistochemistry in breast carcinomas: correlation with overall and disease free survival.

Authors:  C Charpin; S Garcia; C Bouvier; F Martini; M Lavaut; C Allasia; P Bonnier; L Andrac
Journal:  J Clin Pathol       Date:  1997-07       Impact factor: 3.411

2.  Prime region subsite specificity characterization of human cathepsin D: the dominant role of position 128.

Authors:  B M Beyer; B M Dunn
Journal:  Protein Sci       Date:  1998-01       Impact factor: 6.725

3.  Immunohistochemical and clinical evaluation of cathepsin expression in soft tissue sarcomas.

Authors:  P Würl; H Taubert; A Meye; T Dansranjavin; E Weber; D Günther; D Berger; H Schmidt; H Dralle; F W Rath
Journal:  Virchows Arch       Date:  1997-03       Impact factor: 4.064

4.  Lymph node status as a guide to selection of available prognostic markers in breast cancer: the clinical practice of the future?

Authors:  A Elzagheid; T Kuopio; S Pyrhönen; Y Collan
Journal:  Diagn Pathol       Date:  2006-11-08       Impact factor: 2.644

5.  Relationship between cathepsin-D content and disease-free survival in node-negative breast cancer patients: a meta-analysis.

Authors:  G Ferrandina; G Scambia; F Bardelli; P Benedetti Panici; S Mancuso; A Messori
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

6.  Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors.

Authors:  T Jahkola; T Toivonen; K von Smitten; I Virtanen; V M Wasenius; C Blomqvist
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.